The abstract is read at the publisher; the summary is JClub's.
MTAP loss is detected in 17% of 243 non-small cell lung cancers, including 24% of stage 4 driver-positive tumors, highlighting a frequent, actionable biomarker.
- Why it matters: Next-generation sequencing may underestimate copy loss, and it is unclear how PRMT5 inhibitors perform in oncogene-driven NSCLC beyond MTAP status.
- What they did: MTAP expression was measured by immunohistochemistry in 243 NSCLCs (132 early stage, 111 metastatic) with 33 paired lymph-node specimens, and PRMT5 inhibitor monotherapy or TKI combinations were tested in 22 MTAP-deleted cell lines (EGFR, KRAS, or ALK).
- The result: PRMT5 inhibitor sensitivity varied across MTAP-deleted lines and was not predicted by SDMA expression; adding TKIs increased activity versus monotherapy, supporting PRMT5 inhibitor plus TKI evaluation in oncogene-driven NSCLC.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.